Site Search
Professionals 225 results
Capabilities 51 results
Industry
Winston has been a major player in the life sciences industry for decades. We represent market-leading clients across this broad sector, including companies involved in pharmaceuticals, biologics, biosimilars, biotechnology, and medical devices. Our attorneys are seasoned practitioners—many of whom have technical degrees in areas key to the life sciences sector, including biology, chemistry, pharmacy, and biomedical engineering—and bring a unique understanding of the industry and perspective to our representations.
Industry
The medical device industry is currently undergoing monumental change—from supply chain challenges to disruptive technologies and economic fluctuations. To pave the way for a more accessible and innovative health care landscape—including advances in wearables, implants, diagnostics, mobility, drug delivery—the evolving and expansive medical device industry faces wide-ranging legal needs. Clients in this sector can tap the remarkable depth and breadth of our sector-focused and skilled attorneys in the U.S. and abroad. Our Health Care & Life Sciences Industry Group engages clients at all points in the product development life cycle to provide sound advice and practical solutions regardless of the client’s size or the complexity of their need. We help clients navigate today’s complex regulatory landscape, defend products and reputations in the face of high-profile product liability and mass tort claims, protect innovative intellectual property (IP), and leverage cross-border experience to advise on commercial transactions.
Experience 26 results
Experience
|October 16, 2023
Docter Inc. and Aimfinity Investment Corp. I Announce Definitive Merger Agreement
Experience
|August 17, 2023
Winston Serves as Trial Counsel in Monsanto Roundup Litigation
Experience
|March 8, 2023
GIO World Health Business Combination with Apeiron Capital Investment Corp.
Winston & Strawn is representing GIO World Health, a recently formed company focused on stem cell research and development, in its announced business combination with Apeiron Capital Investment Corp. (OTC: APNC), a publicly traded special purpose acquisition company. Upon closing, GIO World Health will become public in order to bring its proprietary stem cell treatments to market and other stem cell-based products for global consumption. The parties intend that at the closing of the proposed transaction, Apeiron Capital common stock will be listed on either the NYSE or NASDAQ, and Apeiron Capital will be renamed "GIO World Health Holdings, Inc." Under the business combination agreement (BCA), Apeiron Capital will acquire shares of GIO World Health from its existing shareholders in exchange for newly issued common shares of Apeiron Capital. GIO shareholders holding approximately 98.7% of its outstanding shares have signed on to sell their shares to Apeiron Capital under the BCA, and the parties intend to have the remaining GIO shareholders participate in the transaction prior to the closing. Under the terms of the BCA, GIO World Health is valued at a pre-money enterprise value of US$250M.
Insights & News 1,049 results
Seminar/CLE
|June 4, 2024
2024 Health Care & Life Sciences Summit
Winston & Strawn is pleased to host our Annual Health Care & Life Sciences Summit on Tuesday, June 4, 2024, both virtually and in person in our Chicago office.
Seminar/CLE
|May 9, 2024
Winston’s Product & Mass Torts Summit Series 2024
Winston & Strawn is pleased to kick off our Product & Mass Tort Summit—a series of panels to be presented in key U.S. markets. The first one-hour CLE panel in the series will bring together Winston partners along with in-house counsel Bill Childs (Solventum) and David Mendelson (Abbott Laboratories) to dig into practical and actionable considerations for corporate counsel in managing product liability and mass tort cases.
Speaking Engagement
|April 25, 2024
Ivan Poullaos Discusses Jury Trial Preparedness in ANDA Cases at Paragraph IV Disputes Conference
Winston & Strawn partner Ivan Poullaos will speak at the 20thAnnual Paragraph IV Disputes Conference, April 25-26, 2024, in New York City.
Other Results 38 results
Site Content
Law Glossary
Emerging technology is a term generally used to describe a new technology, but it may also refer to the continuing development of an existing technology; it can have slightly different meaning when used in different areas, such as media, business, science, or education. The term commonly refers to technologies that are currently developing, or that are expected to be available within the next five to ten years, and is usually reserved for technologies that are creating, or are expected to create, significant social or economic effects.
Law Glossary
Consumer privacy law is the legal area covering violations of personal information and the right to privacy in everyday life, including violations relating to technology use and finances. Consumer privacy laws and regulations protect individuals from privacy loss due to the failures and limitations of corporate customer privacy measures. The Federal Trade Commission (FTC) is the primary agency directing federal privacy policies and enforcing associated regulations. The FTC utilizes law enforcement, creates policy, and educates consumers as it acts to protect privacy. Legal action can be taken against organizations that violate consumer privacy rights, especially regarding sensitive information.